g r a e b e l c€¦ · verenium / basf 60,000 sf tenant representation genzyme / sanofi 64,000 sf...

20VOLUME 24, ISSUE 1 Sp r i n g 2015

10

17

18LifeLinesFor the Southern California Life Science Community

Nudging Out 2014, Sweeping In 2015

Come Ignite Your Love for STEM

Biocom Your Move

IT WAS TWENTY YEARS AGO: BIOCOM LOOKS BACK AND AHEAD

CEL

EBRA

TING

YEAR

S

Dexcom, Inc.218,000 SF

Tenant Representation

Biocom10,900 SF


AltheaDx70,000 SF


Mirati Therapeutics18,000 SF


Verenium / BASF60,000 SF


Genzyme / Sanofi64,000 SF

Sale Disposition

Arcturus Therapeutics10,000 SF


TORREYANAApril 3, 2013

San Diego, CA

Exterior View @ South Facade

Cubist45,000 SF

Sublease Disposition

Genomatica70,000 SF


CELEBRAT ING 20 SUCCESSFUL YEARSWelcome to our first edition of LifeLines for 2015, celebrating Biocom’s 20th

anniversary year as the voice of Southern California’s life sciences industry. As I

complete this column, Biocom’s new offices have just been completed in the ARE Life

Science Industry Community Center on Torrey Pines Mesa. My team and I look forward

to maintaining a strong relationship with our members on the Mesa, and welcoming

members and visitors from throughout the region and the world to this state-of-the

art building, which will allow us to more effectively network and advocate for our

community.

Our cover story this month looks back on 20 years of Biocom history – where we were

then and how far we have advanced today to become the largest regional life science

association in the world. Written by former Biogen Idec director of Investor Relations

and Communications Vince Reardon, it provides a unique perspective from a 30-year

San Diego life sciences veteran.

With Biocom’s continued strong efforts in public policy on the local, state and

national level in full swing, this issue reviews our recent roundtable with San Diego

Mayor Kevin Faulconer; our January life sciences briefing with members of the

State Legislature, including Assembly Speaker Toni Atkins and Select Committee on

Biotechnology Chair, Assembly Member Kevin Mullin; the digital health members fly-in

hosted by our Washington, D.C., office; and a look ahead at the 21st Century Cures

legislative package.

Our key Biocom initiatives all continue to grow and you will read about several of

them here. Our CRO initiative has its own web site at biocomcro.org, and this month

Biocom board and executive committee member Tim Scott, who chairs the initiative,

will tell you more about CROs in Biocom. Our San Diego Festival of Science &

Engineering, which focuses on making teachers, students and parents more aware of

career opportunities in the field, will be held this March. In this edition, you will learn

more about what to expect at the event. And speaking of events – another strength of

Biocom over the last 20 years – this month we feature a guest article from Life Science

Leader magazine, our partner on the conference this August called Outsourced Pharma

West.

As if that is not an aggressive enough agenda, we also feature articles on the other

important pillars of Biocom. Our Biocom Institute has exciting plans for this year,

including our Festival, as well as a Veterans Training Program, a Teacher Fellows

Program and the return of our STEM Voice Video competition. The Biocom Purchasing

Group, which has increased its offerings to our members significantly over the past

year, reviews a new program called, Biocom Your Move Program, which pulls together a

number of different vendor contracts to collectively assist in your facility move.

Please enjoy this anniversary issue and come by to see us in our new facility as we

continue to accelerate the success of the regional life sciences industry.

2 Cover Story: It Was Twenty Years Ago: Biocom Looks Back and Ahead

Biocom Timeline: Looking back 20 years

10 Public Policy : Nudging Out 2014, Sweeping In 2015

11 Guest: The Biocom CRO Group: Transforming San Diego’s Life Sciences Outsourcing Industry

12 Guest: Venture Capital Outlook Optimistic as IPO, M&A Streaks Continue

14 Guest: A forum on the business of outsourcing is coming to San Diego

16 Biocom Institute: What are We Doing Now?

17 Science Festival: Come Ignite Your Love for STEM

18 Purchasing Group: Biocom Your Move

20 Premium Member Spotlights: EY, Pfizer, Latham & Watkins, Wilson Sonsini Goodrich & Rosati

22 Biocom Board and Committees

23 Biocom Membership

EDITOR : Jennifer LandressCOPY EDITOR : Josh BaxtDESIGN & LAYOUT: Arlene Arreola

V O L U M E 2 4 , I S S U E 1

WELCOMEI N T H I S I S S U E

WWW.BIOCOM.ORG

By Joe Panetta, President and CEO, Biocom

Biocom, a member driven organization is here to assist life science companies like yours to fulfill your most ambitious goals. We can help your company with saving money, advocacy, increased visibility, networking opportunities, capital development and workforce development.

8-9

Biocom LifeLines Spring 2015 1

Opportunity comes in many disguises and loiters at the most unlikely crossroads. In 1991, San Diego was in the grip of a long and severe drought. The San Diego City Council and Mayor Maureen O’Connor were struggling to find ways to conserve water. One plan was to impose draconian water rationing measures on local manufacturers. The proposal called for some companies to get water in the morning, others in the afternoon. The organization that would ultimately becomen Biocom was conceived during this crisis.

“Things were looking pretty bleak,” said Guy Iannuzzi, president of Mentus. “Obviously, the council didn’t know about the industry’s need for water.”

David Hale, then president of Gensia and the former president of Hybritech, became the spokesperson for the industry. Everybody knew him.

Hale said: “This is nonsense! We can’t live with this. We’re going to change it.’ He called other CEOs in the industry and some of

the service providers together – lawyers, architects, and commercial real estate agents – and said, “We have to go to the City Council and tell them this isn’t going to fly.”

Hale got then-Councilman Ron Roberts to schedule a biotech day with the City Council. “I made a presentation on behalf of the industry and we had four companies that talked about the industry, about what

they were doing,” said Hale, now Chairman and CEO of Hale BioPharma Ventures, LLC. “It was about a three hour session. The Council had no idea what the industry was doing. But the important thing that came out of it was the council appointed a special liaison, an ombudsman, within the city government to work on our issues. That was a real success.”

The mayor and the council got the message and scuttled the water rationing plan. “After that meeting, I pulled together the same group and started the Biotechnology Industry Council (BIC),” Hale said. BIC consisted primarily of biotech CEOs, such as Bill Rastetter, the late Duane Roth, Howard Birndorf and included the late Bill Otterson of UCSD Connect.

An Industry in Search of an Organization“The industry became self-aware,” Iannuzzi said. “From that

It Was Twenty Years Ago: Biocom Looks Back and Ahead

COVER S TORYBy Vince Reardon

years

CELEBRATING

#Biocom20

20 S U C C E S St h r o u g hCO M M U N I T Y

“WITHOUT B IOCOM, SAN D IEGO WOULDN’ T BE THE L I FE SC IENCES HUB THAT I T I S .” - -GREG LUC IER , FORMER CHAIRMAN AND CEO OF L I FE TECHNOLOGIES

2 Biocom LifeLines Spring 2015

COVER S TORY

m o m e n t , we realized we could speak to the c ommun i t y and the commun i t y would listen. We could affect a change.”

As BIC was taking shape, the late Jim McGraw of McGraw/Baldwin Architects, Wain Fishburn, now of Cooley LLP, Brent Jacobs, now of Cushman Wakefield, and Iannuzzi created a second organization, called the San Diego Biocommerce Association.

“The operating theory was that this group could lobby more effectively and with less exposure or risk than the biotech companies,” said Ken Baldwin of Ferguson, Pape Baldwin Architects.

BIC and the San Diego Biocommerce Association existed as parallel organizations for about four years, until members of both groups recommended consolidation. But what to call the new organization?

“I suggested abbreviating the San Diego Biocommerce Association to simply Biocom,” said Baldwin. “It had a nice ring to it.”

The new name was chosen to suggest bio-commerce, bio-communication, and bio-community. The name was quickly adopted and has been widely embraced ever since.

Ironically, what began as an informal committee united behind one issue – water – evolved into an official organization in May 1995 with one common vision and purpose: to promote and support life science companies in the region. Duane Roth was named the first chairman of Biocom and Ann Randolph the first managing director.

In 1999, the board recruited Joe Panetta, formerly the vice president of government and public affairs at Mycogen, to serve as Biocom’s first President and CEO. Under Panetta’s skillful stewardship Biocom has developed programs that have delivered, and in some cases anticipated, members’ needs in five key areas: capital development, public policy, professional networking and communications, group purchasing and workforce development.

Capital DevelopmentEven before the merger of BIC and the San Diego Biocommerce

Association, the two groups were working together to bring investors to San Diego. In 1992, they organized the first CalBio Summit to showcase the sector to venture capitalists, Wall Street investors and distinguished elected officials, including then Governor Pete

Wilson.Over the years the CalBio Summit, now called CALBIO, has

grown in size and stature. “It’s truly a statewide conference today,” said Carin Canale of Canale Communications. “If you’re a biotech entrepreneur in California and you only attend one conference throughout the year, from an education, partnering and networking perspective, CALBIO is the one to attend.”

For example, the last CALBIO in 2013 attracted numerous venture capitalists from the Bay Area, as well as potential partnering companies from the both coasts, including Eli Lilly, Pfizer, Sanofi and Johnson & Johnson.

Last year, there was no CALBIO. Instead, Biocom hosted the 2014 BIO International Conference in June and achieved record attendance. More than 15,000 industry leaders, including nearly 2,500 CEO’s from 50 states and 70 countries attended.

The convention featured keynotes from Sir Richard Branson and former Secretary of State Hillary Rodham Clinton. In addition, there were more than 800 speakers and 160 sessions in eight educational tracks and nine specialty forums, which addressed the latest business opportunities, breakthroughs in medicine, diagnostics, the environment, energy production, food and agriculture and more.

“Biocom’s strength and depth in capital development has grown tremendously,” said Canale. “In addition to “Venture Speed Dating” during CALBIO, several times a year we invite out-of-market venture capitalists to San Diego to meet with companies. Recently we had Canaan Ventures, InterWest Partners and Fraiser Ventures all in the room at the same time. To get funds collectively worth a couple of billion dollars to come to San Diego and spend the day with emerging companies is hard to come by and a true value-add to Biocom members.”

In recent years, these meetings have produced significant financial transactions for local life science companies. “In the last two years (2013-14), we’ve seen an incredible number of company creations, financings, successful exits, such as initial public offerings (IPOs), as well as acquisitions, which have been unprecedented in our industry” said Magda Marquet, Ph.D., founder and co-chairman of Althea Technologies. “The climate has been very, very healthy financially.”


COVER S TORY

Public PolicyOne of the major roles Biocom has played over the last 20 years

has been shaping public policy locally, regionally and nationally. “The breadth of public policy support Biocom provides the industry has always been impressive,” said Baldwin. “For example, it has a political action committee and a significant lobbying presence in both Sacramento and Washington, D.C. It didn’t take too many instances of ‘We’re not getting what we want out of these processes’ to create a structure to address it, and usually in advance of when the actual need was there.”

Forward thinking and political action paid dividends in 1993-94 when the Clinton Administration was promoting its health care plan. “We went back to Washington, D.C., half a dozen times with Biocom and Connect,” said Hale. “We met with Ira Magaziner, the administration’s health care czar, as well as Hilary Clinton, on the health care bill.”

By 1994 Senate Majority Leader George Mitchell declared the Health Security Act dead, following withering criticism from the biopharmaceutical industry, with input from Biocom, as well as the business sector in general.

“Besides successes in Washington, D.C., Biocom has also been very effective at the state level, working with legislators and Governor Brown on issues that affect our industry and the state,” Hale said.

Over the years, the issues have ranged from successfully advocating for elimination of duplicative state inspections of facilities already inspected by the Food and Drug Administration (FDA), to enactment of industry-specific state sales tax relief for equipment used in

research and d e v e l o pmen t , to ongoing monitoring and lobbying when state legislation has unintended consequences for the life sciences industry.

M e a n w h i l e , Biocom remains actively involved

in local issues critical to the industry. “Biocom has worked with the Mayor’s office to add a quarterly roundtable discussion,” said Canale. “On a quarterly basis we meet with the mayor and his team to discuss life sciences and what the city can do to continue to support one of the driving forces of the San Diego economy.”

Professional Networking and CommunicationsAs the life sciences industry has matured over the past 20

years, Biocom has become the premier organization in the region, bringing interested parties together from all sectors of the community: public and private companies, research and educational institutions and government agencies.

“When I came to San Diego 16 years ago, I was new to the West Coast,” said Alex Lukianov, Chairman and CEO of Nuvasive. “Biocom was terrific from the standpoint of networking in those early days, especially

getting to know the community and meeting people on the Biocom board. Over the years that’s blossomed into a series of professional friendships with local company CEOs and VCs. I have always been

pleased with Biocom’s networking capabilities.” Biocom also provides tools and resources for entrepreneurs in

life sciences. “These can range from mentoring help in getting capital, to assistance with outsourcing needs, to having your voice heard in Washington or Sacramento,” said Marquet. “Biocom has not only grown with the industry, it has also anticipated the needs of the industry. That’s impressive.”

Group Purchasing Since its inception, Biocom has been able to deliver significant

savings to members on the purchase of supplies and equipment. “If you look at the benefits of Biocom’s Purchasing Group, it’s simple statistics,” said Baldwin. “Everyone understands hard numbers. If you join Biocom, you’re going to save tens of thousands of dollars or more, depending on your scale.”

There are more than 40 member vetted contracts endorsed by Biocom, which translate into significant volume savings and favorable terms on products and services frequently used in the

“BIOCOM HAS NOT ONLY GROWN WI TH THE INDUSTRY, I T HAS ALSO ANT IC IPATED THE NEEDS OF THE INDUSTRY. THAT ’S IMPRESS IVE .” - -MAGDA MARQUET , CO-FOUNDER, AL THEA (A MEMBER OF THE A J INOMOTO GROUP)


life science industry. “If you don’t join Biocom, it’s not because of membership cost,” said Baldwin. “There is a direct offset available to you if you use the Purchasing Group.”

Workforce DevelopmentFor years Biocom has been in the forefront of helping companies

develop the skills of their employees. Sixty-one percent of all jobs in California, approximately 12 million jobs, will require some post-secondary training beyond high school in 2018, according to workforce development experts. Biocom is out in front of those numbers by supporting local educational institutions.

“We have a wonderful workforce opportunity in our region,” Canale said. “We have institutions of higher education that are flexible and forward-thinking in the degrees they offer students. In addition, Mira Costa Community College and Palomar College offer various technical, biomedical and bioprocessing certificates that prepare students for real jobs in life sciences labs.”

In addition, the Biocom Institute offers various professional development programs, such as a management training certificate through the Leadership Edge, networking and professional development for women in the life sciences through Women in Bio and presentation training through 2Connect.

There are also Biocom Institute programs to strengthen proficiency in science, technology, engineering and math (STEM) in our city schools, such as the annual San Diego Festival of Science & Engineering and the Teacher Fellows program exposing K-12 STEM Educators to the life science industry. And there are training and technical programs to support returning veterans from Iraq and Afghanistan, such as the existing veteran career mentoring program and Fatigues to Lab Coats, a program in development that will train veterans to be bio technicians.

Biocom’s workforce development is helping the life sciences

industry stay up-to-date as employment trends and industry needs change. “San Diego is building this incredible combination of basic research, drug development capabilities and now increasingly – with all the medical center building going on – a place to be treated as well. San Diego is becoming not only a life sciences hub but also a healthcare hub,” said Greg Lucier, former chairman and CEO of Life Technologies.

Looking Ahead“Biocom is a tremendous success story because of its central

focus on the life sciences ecosystem, because of its strong leadership under Joe Panetta, and because of the broad participation of its member companies, which have allowed San Diego to become the place to practice life sciences,” said Lucier. “Without Biocom, San Diego wouldn’t be the life sciences hub that it is.”

So what can one expect from Biocom in the years ahead? Look for continued support of existing programs and the initiation of a wide range of new programs and activities supporting the regional life science industry on a global scale.

For starters, San Diego is truly the world leader in the exciting area of genomics and Biocom is working diligently to support this new growing sector. “In San Diego you have Illumina and other genomics companies, like Sequenom, Edico Genome and

BioNano,” said Canale. “Then, you have Dr. Eric Topol at Scripps Research Institute. You have the Moores Cancer Center, which is saying it’s going to sequence every cancer patient that walks through the door. And of course, there’s Craig Venter, who sequenced the human genome. When he wanted to build his research institute, where did he come? He came to San Diego.”

Biocom is also supporting the emerging convergence of life sciences and wireless technologies. “When Biocom started, its focus

was addressing the needs of drug development companies,” said Marquet. “Then, it became diagnostics and medical devices. Later, it reached out to industrial biotechnology companies. Now it’s digital health, mobile health, which is really growing. San Diego is the capital of wireless health in the world. By incorporating this growing area into Biocom, I think we respond to the current needs and future needs of the industry.”

Biocom is also promoting the maturation of medical device companies in the region. “We’ve been a little bit of a well-kept secret for many years – well known for biotech, not so much for medical device companies,” said Lukianov. “But I think that’s changing. As I contrast the last decade with the prior decade, I would say things have dramatically improved relative to our stature

COVER S TORY


Innovative virtual product development approachMultidisciplinary strategy and plans from early stage to exit

Team of industry seasoned experts excel in delivering solutions for risk controlIntegration of technical and commercial considerations to maximize product value

Atheln is a Contract Development Organization delivering solutions to biopharma companies

www.athelnbiomed.com

Atheln-BioCom-Ad-Feb2015-final.indd 1 2/9/15 2:47 PM

in San Diego as a biotechnology, medical device, life sciences community. I think going forward that is only going to get better because we have a great brain trust here.”

Biocom will also continue to look for opportunities abroad. While its focus is principally local and regional, it frequently travels abroad to lure foreign companies and investors to the local life sciences community. “In the last few years, Joe Panetta and a delegation of Biocom board members and CEOs have worked to grow Biocom and San Diego’s reputation across Asia,” said Canale. “Because of this tireless work, we are largely considered the example to follow when it comes to building life science regions or the partner of choice for companies looking to build trans-Pacific relationships.”

Biocom has conducted four trade missions from 2009 to 2012 and has established new relations within China’s emerging life sciences industry. It has also introduced Biocom members to their counterparts in China. After visiting France and Japan last year, Biocom welcomed companies from both countries into its membership. In addition, Biocom has signed MOU’s with these

respective regions to futher opportunities for members to engage with International groups.

Peter Drucker said: “To build achieving organizations you must replace power with responsibility.” From its earliest days,

that’s what the two organizations that merged into Biocom did so successfully. Instead of bickering and posturing, the pioneers of Biocom rolled up their sleeves and responded to an existential threat – a drought.

But could anyone have predicted the organization’s success over the past 20 years? “No, I don’t think anyone could have had that vision,” said Hale. “I did think that it was something that we would continue to need because there are a lot of issues that come up that are very difficult

for one company to tackle. I did feel from the very beginning that having an organization that represented the industry here in San Diego was going to be very important and sustainable and could continue to have an impact.”

Vince Reardon is a freelance writer in San Diego. He is the author of the recently

published The Pocket Mentor: Insider Tips from America’s Most Successful Americans.

BIC and San Diego Biocommerce Association vote to merge as BIOCOM/San Diego.

Biocom Purchasing Group created.

Launched the Capital Development Initiative and hosted the 1st Annual Investor Conference.

Launched the 1st Annual Global Partnering Conference focused on bringing together top licensing and BD professionals from around the globe to a two day conference in San Diego.

Launched a career site, a job site exclusively for Southern California companies.

The San Diego Festival of Science & Engineering finds its new home in Biocom.

Retained Sloat, Higgins, Jensen & Associates as its Sacramento lobbying firm, giving it a constant, on the ground presence in the state capitol for the first time.

Biocom plays a critical role in passage of California’s adoption of an optional single sales factor corporate income tax apportionment so that companies are no longer penalized for the size of their CA payroll.

Biocom and key members come together to create the CRO Initiative. www.biocomcro.org.

Launched the scholarship and education fund.

‘95 ‘96 ‘97

‘06‘08

‘11

‘07

‘12

‘05

‘09 ‘10

years

CELEBRATING

20

The Biocom Institute is created.

1st Annual Life Sciences Night at the Opera event.

Hosted the 1st Annual Nobel Laureate Dinner to honor the six Nobel Prize winners in chemistry, physiology and medicine who live in San Diego.

Opened an office in Carlsbad, recognizing the need to focus on life science companies in North County.

Opened a full time Washington DC Office. Biocom was instrumental in supporting the Governor’s economic development package, which, among other things, exempted equipment used in R&D from state sales tax.

The launch of BiocomConcierge.com – a web site that connects member needs with the services of a fellow Biocom members.

Relocated to our permanent home on the Torrey Pines Mesa and celebrates 20 years of being the accelerator for the life sciences industry in Southern California

The passage of Prop. 71 which provided $3 billion funding for embryonic stem cell research in CA over ten years.

First Biocom Annual Dinner with keynote speaker Naomi Judd.

Joe Panetta joins as President and CEO.

‘98 ‘99 ‘00 ‘01

‘02

‘13 ‘14 ‘15

‘04 ‘03

The world’s biotechnology convention converges on San Diego for BIO 2001.

As we begin 2015, new delegations have been seated at the federal, state and local levels of government. With that comes the responsibility of educating a whole new group of policy-makers about the life sciences industry and its importance to the Southern California economy. The faces change, but some of the legislative fights of 2014 will continue this year.

In December, Biocom hosted our 2014 Washington DC Digital Health Advocacy Fly-In, which brought together San Diego companies operating in the digital health space and federal officials to discuss the needs and challenges of this sector. Participants started the day meeting with top management for the Center for Device and Radiologic Health (CDRH) of the FDA, including CDRH Director Jeff Shuren. They then went to Capitol Hill, meeting with key Congressional staff. The event concluded with a meeting at the Office of the National Coordinator for Health IT (ONC), within the Department of Health and Human Services (HHS), with policy director Jodi Daniel.

At the state level, Biocom worked closely with the California Biotechnology Foundation on the program for Speaker Toni Atkins’ and Speaker Pro Tempore Kevin Mullin’s January briefing for new members of the State Assembly. Biocom board chair-elect, Dan Burgess, and longtime San Diego biotech executive, Laura Shawver, educated legislators on the complexity of the industry, as well as its importance to the California economy.

Locally, the San Diego City Council gave final approval in November to a compromise plan for changes to the linkage fee. Working on behalf of our members, Biocom and our coalition partners were able to negotiate maintaining current fee levels for research and development construction. Other provisions include returning the fee to its 1990 level over the next three years (a 100 percent increase for industries other than R&D) and a strong regulatory reform package.

In December, Biocom held a roundtable discussion with our members and Mayor Kevin Faulconer to discuss the linkage fee, flooding mitigation in Sorrento Valley and economic incentives for businesses. Mayor Faulconer vowed to work with Biocom members to change city processes governing building and permitting. These roundtables will continue in 2015.

Looking into the coming year, the San Diego Congressional delegation is unchanged, and the Orange County delegation gained a long-time friend of the industry, and Biocom, in Congresswoman Mimi Walters. We are excited about continuing to work with this group.

The industry will have to fight against those who would weaken patent protections and the ability to defend intellectual property rights. This was one of the industry’s biggest legislative challenges in 2014, and will continue to be a priority in 2015, as will aggressively advocating for the repeal of the medical device tax.

As of this writing, the House Energy and Commerce Committee has just released a preliminary discussion draft regarding its long-awaited 21st Century Cures legislative package. This proposal will likely encounter many twists, turns and changes as it navigates the process, and we encourage you to stay apprised of these via Biocom Biocommunique, our email newsletter, which is distributed every two weeks.

The life sciences industry continues to lead California’s economic recovery as one of the state’s most robust growth areas. With the recent FDA staff recommendation for approval of a biosimilar, it is important that a proper substitution pathway be established at the state level. Biocom is also watching closely to see if bills attempting to make manufacturers bear the burden of California-specific drug take back and sharps take back programs are re-introduced in this new session of the legislature. The public policy department, and Biocom’s contract lobbyist in Sacramento, continue to monitor legislation that will specifically impact the life science industry in California.

We are prepared for a challenging and exciting policy year. Please keep an eye on the BCQ for the most current information, and feel free to contact us if you have questions.

Jimmy Jackson is the Senior Vice President of Public Policy for Biocom. He oversees government affairs and public policy for the organization.

PUBL IC POL ICY

Nudging Out 2014, Sweeping In 2015

By Jimmy Jackson, Senior Vice President of Public Policy, Biocom


The story of Akio Morita, founder and former chairman of Sony, is not just a story about developing an iconic brand; it is also a tale of redeveloping an entire country. Started in 1946 in the basement of a department store, Sony grew over the next 50 years to become the number one consumer brand name in the world. But just as important, by insisting on producing the most innovative, highest quality products – made with cutting-edge technology – Morita transformed the Japanese consumer electronics industry, elevating it to equal the highest quality technology companies anywhere.

A similar transformation is occurring in the Southern California life sciences cluster. What was once a handful of small mom and pop contract analytical and testing laboratories has blossomed into a center of pharmaceutical development excellence known around the world.

Biocom launched its CRO Initiative in 2010 to support the growing community of contract research organizations (CROs), which include contract development and manufacturing, clinical research, toxicology and other life science service providers. The CRO Committee began with 22 members in 2010, representing 198 employees. Today, the group consists of 86 members, with more than 1,600 employees in Southern California, providing services for biopharma companies over the entire range of pharmaceutical drug development – from animal studies to human clinical trials.

Since the early 90’s, the San Diego biotech industry has evolved from integrated pharmaceutical and medical device companies discovering new compounds and technologies to companies that deliver compounds and technologies to the clinic using an increasingly diverse host of outsource providers. This evolution has dramatically improved the ability to move new drugs and devices to the clinic. In particular, labor and resource efficiencies have helped companies bring more drugs to patients at lower cost. At the same time, this biopharma evolution has also created a burgeoning industry of life science service providers, which have grown up to serve sponsor-driven science.

As Southern California’s contract research industry has grown, so has the sophistication of its systems and the quality of its programs. Companies have improved their facilities, engineering controls, quality systems and training programs to become world-class science organizations. The local entrepreneurial attitude has remained, and now it is supported by state-of-the-art programs and facilities.

The growth of San Diego’s CRO industry is based, in large part, on talented people who supply the skills and knowledge to provide development services.

Southern California’s intellectual network connects research institutions, such as UC San Diego, UC Irvine, The Scripps Research Institute, Salk Institute, Sanford-Burnham and many others, to fuel the innovation economy. This network, along with the undergraduate

programs at UC San Diego, UC Irvine, San Diego State and the University of San Diego, provides talented students in biology, chemistry, chemical engineering and computer science to create a dynamic and intelligent workforce. In turn, this workforce provides the talent to discover new technologies, manage their development and provide the services to bring them to fruition.

In addition, the pharmaceutical industry’s workforce reduction over the last five years has created an interesting dynamic between the pharmaceutical and medical device industries and the service providers that support them. More than 250,000 scientists and engineers have been laid off since 2008. This talent loss has led pharmaceutical and device companies to outsource even more of their research and development activities. While some of these employees retired, many took positions with service providers or created their own outsourcing companies to provide services for the same companies that once employed them. This created a massive movement of science and engineering knowledge from one end of the industry to the other. As a result, Biocom CRO members and other life science providers are stocked with talented people.

While it was clear that local CROs, like pharmaceutical and biotechnology companies, have enjoyed taking advantage of Biocom’s membership benefits, the addition of the Biocom CRO Group has enhanced the community. For example, an educational seminar series has trained more than 2,400 Biocom member scientists on clinical trial strategies, medical devices, biomarkers, bioanalytics, formulation development, international collaborations, novel funding strategies, toxicology, managing outsource providers and a host of other topics.

Akio Morita transformed a company, an industry and a country. The Biocom CRO Group is working to transform San Diego into the best region for outsourced research and development in the industry. This leadership is built on a passion to provide the highest quality services for drug and device development. It is also built by a group of disparate service providers working together towards a common goal: creating a region with best-of-class service in each development area.

The Biocom CRO Group is branding the San Diego region as the place to go for development services, from discovery through development and clinical trial management. Thanks in part to the efforts of the Biocom CRO Group, today, the world comes to San Diego to develop pharmaceutical drugs and technology.

Tim Scott is the President of Pharmatek, the Chair of Biocom’s CRO Committee and serves on Biocom’s Executive Committee and Board of Directors.

GUEST

The Biocom CRO Group: Transforming San Diego’s Life Sciences Outsourcing Industry

By Timothy Scott President, Pharmatek Laboratories, Inc.


Big pharma companies have billions of dollars at their disposal for acquisitions and partnerships, but so do large biotechnology and specialty pharmaceutical firms, and they are keen competitors for novel drugs and development approaches.

Ernst & Young (EY) said in its recent report Firepower Index and Growth Gap Report 2015: Firepower Fireworks that big pharma invested $90 billion in mergers and acquisitions in 2014, but specialty pharma companies spent $130 billion on M&A. Specialty drug makers’ desires to become larger global players made them willing to outbid big pharma companies, which need to replenish their research and development pipelines to maintain their market status.

Meanwhile, big biotech companies tend to focus more on licensing and partnership deals than on M&A, but EY noted that rapidly increasing sales for companies like Celgene and Biogen Idec are boosting their deal making “firepower.” Those firms are putting their billions of dollars in cash to work in various collaborations, often with early-stage companies that may struggle to raise capital from investors.

Early-Stage OpportunitiesThe MoneyTree Report from PricewaterhouseCoopers (PwC) and the

National Venture Capital Association (NVCA), with data from Thomson Reuters, noted that biotech companies raised $6 billion in 2014, the most money since 2007. However, fewer biotechs were able to get venture capital last year: 112 companies raised $2 billion in the fourth quarter compared with 144 biotech firms that raised $1.4 billion during the last quarter of 2013. There were fewer first-time financings as well.

But NVCA also reported recently that in 2014 corporate venture capital reached its highest level since 2000, with $5.4 billion invested by corporate VC funds, including $810 million that pharma and biotech corporate VC funds invested in 98 life science companies. That means the industry is stepping up its investments in the earliest stages of drug, medical device and diagnostic development.

The Japanese big pharma Astellas launched Astellas Innovation Management (AIM) in late 2013 to work with venture capital firms, biotech startups and academic researchers.

“We’re investing in emerging biology,” AIM vice president Shunichiro Matsumoto said.

Flexible dealmakingLarge biotech, big pharma and specialty drug makers are discerning

about the small and mid-sized biotech companies that they’ll collaborate with or buy. However, they’re also becoming more flexible about deal terms to make transactions work for them and their partners.

Shire acquired Lumena Pharmaceuticals for $260 million in May 2014, but rather than replace all of the company’s employees and install new overseers for ongoing clinical trials, Shire left most of the Lumena team in place in San Diego to keep programs in the treatment

of cholestatic liver diseases on track. “We’re not a company that just takes assets from outside; we

keep the people and their expertise,” Shire head of research and development Phil Vickers said.

Celgene, in particular, has a reputation for exploring all kinds of deal structures to find the best fit for all involved. That’s why the maker of the blockbuster multiple myeloma therapy Revlimid (lenalidomide) ranks high in comparison to its peers when it comes to deal making.

Celgene senior vice president of business development George Golumbeski said the company usually prefers licensing deals over acquisitions for earlier-stage drug candidates or platform technologies, because it’s hard to put a concrete value on a preclinical or Phase I program. A licensing deal – even one with an option for Celgene to buy its partner – gives the company a transaction value that makes sense and provides a fair deal value for the collaborator and its investors.

However, Dr Golumbeski said, “If a really good company wanted to be acquired, we would look at it.”

Ranking dealmakersBoston Consulting Group found in its 2014 Biopharmaceutical

Partnering Survey, which queried 65 executives about licensing deals, that Celgene ranks high in several categories, such as allowing its partners to develop and prosper, flexibility on deal terms, alliance management and allowing collaborators to retain control of joint development programs.

Celgene had the highest average score across all attributes, followed by Merck, Johnson & Johnson, Roche, Bristol-Myers Squibb and Eli Lilly. AstraZeneca, Novartis and Novo Nordisk also ranked high.

Sophie Kornowski Bonnet, head of Roche partnering, said the company’s business development team works very closely with Pharma Research and Early Development (PRED), the Roche division run by former Sanford-Burnham Medical Research Institute CEO John Reed. Based on the partnering and PRED divisions’ collaboration, Roche’s business development team is on the hunt for immunotherapy, neurology, infectious disease and diagnostic deals.

“We do creative deals to manage our risk,” Dr. Kornowski Bonnet said.

Dr. Reed noted that Roche is monitoring alternative therapeutic delivery approaches, but the company’s investments in things like gene therapy and RNA-based medicines are limited at the moment.

Mandy Jackson is the West Coast Editor of Scrip Intelligence, a biopharma news website, which can be found at www.scripintelligence.com.

GUEST

Venture Capital Outlook Optimistic as IPO, M&A Streaks Continue

By Mandy Jackson, West Coast Editor, SCRIP Intelligence


ProSciTM

© 2015 ProSci Incorporated. All rights reserved.

prosci-inc.com | [email protected] | 858.513.2638

• >12,000 custom antibody projects completed since 1998• In-house labs and animal facilities in San Diego, CA• 150,000 ft2 of animal facilities on 27 acres• USDA licensed & NIH/OLAW assured facilities • Our custom antibody services are widely cited in scientific literature

Send Us Your Sequence,

Get the Antibody of Your Interest

ANTIGENS

ADJUVANTS

ANIMALSANTIBODIES

ASSAYS

Antibodiesagainst diverse

Experienced with various

formulations of

Wide selection of host species

PolyclonalMonoclonal

Single Domain

Characterization and

functional

NEED ANTIBODIES? GO TO PROSCI.Order Your Custom Antibodies TODAY!

Custom Antibody Services

Antibody development and production expertise is the foundation on which ProSci is built. Since 1998, ProSci has conducted HIV neutralizing antibody research and has been a leading provider of custom antibody services and catalog antibodies worldwide.

Need Antibodies? Go to ProSci.

The inaugural Outsourced Pharma West Conference and Exhibition, held last November in San Francisco, hosted more than 200 professionals, including 40 panelists and 45 sponsors. Participants represented executive leadership from early stage through large pharm and biopharm companies, as well as suppliers and investment firms.

The format fostered an open dialogue on the business of outsourcing, during which attendees engaged in a dynamic back-and-forth on challenges and opportunities. The conversation was unscripted, direct and honest. What follows is a window into two of the program’s lively sessions and a look forward to the 2015 conference in San Diego.

Challenging the “one-stop shop” trendPanel: Matching a Vendor to Your Stage of DevelopmentPanelists: Firelli Alonso-Caplen, Pfizer; Jon Crate, FAI Testing Services; David Enloe, Althea; Joe Guiles, Medivation; Bob Munday, CMC Biologics; Patrick Murphy, Versartis; John Ross, Metrics

An attendee requested advice for small firms that are restricted to working with a single supplier due to resource limitations. Murphy’s experience with a small company differed. “I’m not going to be exclusive. I’m going to go to whoever has the ability at that point in time, the interest to accept the risk of a small company and somebody that I can trust.” Additional commentary also countered. “[Small companies] really can’t afford for things to go wrong. You can send the same sample to multiple labs, and you can get CMOs to compete for your work. Once they compete for that work, you’ve got a feel for whether they can actually do it. If one starts letting down, you’ve already got the other one prequalified.”

The conversation naturally shifted to the trending “one-stop shop” model. Enloe pushed back, commenting, “My observation is that CMOs are a lot more willing to say what they’re good at and what they’re not good at right now. A rising tide lifts all ships, and I don’t see, other than outside of a very few technical areas, where there’s this incredible premium for it to be all one place.” Murphy agreed, “I’ve never actually seen a one-stop shop. I assume that that’s a company that can do everything. I’ve never found one.”

Understanding how venture capitalists assess your presentation Panel: Finding Capital That Matches Your GoalsPanelists: Chris Achar, Genzum Life Sciences; Tiba Aynechi, Novo

Ventures; Kevin Judice, entrepreneur; Julie Papanek, Canaan Partners; Jaisim Shah, Semnur Pharmaceuticals; Mahendra Shah, Vivo Capital; Wayne Koberstein, Life Science Leader

Discussion focused on preparing entrepreneurs to secure funding. Jaisim Shah advised, “There are several areas that you must be prepared to address. One is a clear understanding of the unmet need you are trying to address. Not just the scientific or medical need, but also the business need. Having a clear understanding of your development path and what the FDA expectations may be for developing your product is key.” Papanek issued a warning, explaining, “I have seen some capitalization tables come over with 150 names on them. I would worry that some of those people are not qualified investors and that at some point we will have to figure out how to get their capital out of the company. This is why you should think hard about whose money you are taking.”

Save the date for Outsourced Pharma West in San Diego Outsourced Pharma West Conference and Exhibition August 25-26, 2015, Hyatt Regency La JollaCo-produced by Life Science Leader magazine and Biocomoutsourcedpharmawest.com

Outsourced Pharma West is privileged to come to Southern California in 2015 with the generous support of Biocom. As partners, Life Science Leader and Biocom can further advance the conference’s mission to address key business decisions involved in maintaining relationships for development and manufacturing. This growth is possible only with active participation from Biocom members and the region’s wider community — the players driving Southern California’s leading role in the global development pipeline. We invite you to come together this August for what promises to be another insightful experience.

Biocom and Life Science Leader magazine will co-produce Outsourced Pharma West San Diego in 2015.

Ed Miseta is the Executive Editor for theLife Science Leader magazine

A forum on the business of outsourcing is coming to San Diego

GUESTBy Ed Miseta, Executive Editor, Life Science Leader Magazine


Build on Advantage

TRANSFORMING REAL ESTATE INTO REAL

ADVANTAGEFor every client, advantage is delivering

the broadest, deepest reach and resources

any real estate company offers.

Transforming property into prosperity,

square feet into strong portfolios,

scale into global strength. All in service

of exceptional outcomes that build

real business advantage. Let us put our

actionable perspectives, global reach

and powerful connections to work

for your business.

cbre.com/sandiego-occupier @cbresandiego

The Biocom Institute has a unique role: supporting the existing life science workforce and the business leaders charged with hiring, training and retaining them and nurturing the future workforce all the way down to pre-K. For Biocom members, the Institute provides a career center with discounted job postings, an internship program toolkit and discounted professional development courses in leadership, biotech and med device basics and presentation skills. In 2015, we are launching a free salary survey for participating Biocom members.

As for supporting the community and the future of the life sciences industry, our main programs for 2015 include:

San Diego Festival of Science & EngineeringThe Festival has been a great addition to the Biocom Institute

since coming to us from UCSD in 2013. We couldn’t be happier about all the community exposure our industry gets through the Festival. We especially enjoy the kids’ excited faces on Expo Day and the many other events throughout the community in the preceding week. Please check out the separate article on the Festival in this edition of Lifelines for a glimpse of all the fun activities.

Veteran Career Mentoring and Technical TrainingPiloted in the summer of 2014, the first of three four-month

sessions of our Veteran Career Mentoring program officially kicked off on January 15 with a professionally-led, goal-setting session. The program includes one-on-one mentoring from veterans currently working in executive and management positions in business development, marketing, human resources, science and other areas. In addition, with the opportunity to attend relevant, industry-specific events, veterans are taught how to network. Additional workshops help them improve their career-readiness skills. In development this year, Fatigues to Lab Coats trains veterans to become certified bio technicians, using live, publishable research projects.

Teacher FellowsIn 2015 this program is expanding to provide STEM educators

even more access to life sciences companies. The 30 fellows in the program attend an industry mixer, during which teachers and education outreach and community relations managers will network and begin forming relationships, improving the link between classrooms and industry. Teachers will participate in an

industry job shadow in the summer, during which they spend “a day in the life” of a science, engineering or computer professional. Teachers will again attend an international medical device sector conference being held in San Diego. The AdvaMed conference is expected to draw about 2,500 industry professionals over the three-day conference in October. Lastly, the program includes a best practices seminar, during which teachers will share after-school club and classroom project ideas, successes and challenges.

STEM Voice Video CompetitionLast year, we launched the competition nationally with a heavy

local emphasis and more than 65 percent of the entries, including the first runner up, were from the San Diego region. In 2015, the contest design remains the same. Students in grades 5 -12 create a one-minute video on STEM and compete for cash prizes. Kids will compete at regional levels before a national winner is chosen. We will be recruiting judges and expect to see even more creative videos this year, as well as maintaining a high level of local participation. It’s debatable who has more fun: the kids making the videos or the judges watching them. Last year brought all kinds of creative STEM fun – superheroes, surfing, Legos, mad scientists and more.

As a separate 501(c)3, at the Biocom Institute, we rely heavily on partnerships and volunteer support for all that we do. We encourage you to contact us to find out how you can get involved and help make the next 20 years even better than the last.

Liisa Bozinovic is the Executive Director of the Biocom Institute and also heads Biocom’s HR Initiative.

BIOCOMINST I TUTE By Liisa Bozinovic,

Executive Director, Biocom Institute

What are We Doing Now?


From Saturday, March 14 through Saturday, March 21, festival week events and EXPO Day will engage the entire community of San Diego County. In 2015, we anticipate more than 65,000 kids, parents, scientists, educators and community members will participate in festival week activities. Another 24,000 will attend EXPO Day at Petco Park, where more than 130 local businesses, corporations, and organizations will provide interactive, hands-on science, technology, engineering and math exhibits and activities for budding K-12 science lovers.

Stretching into our seventh year, the San Diego Festival of Science & Engineering inspires students to become tomorrow’s science, technology, engineering, and math (STEM) innovators. San Diego is a hot bed for scientific innovation, offering a uniquely collaborative spirit, high concentration of world-class research institutions and a strong foundation for new company creation and development.

Presented by Illumina, the festival is a catalyst to transfer that knowledge and collaboration, showing students and their parents how science, technology, engineering and math translates into careers and further fuels our local economy. Science is all around us and is the foundation for much of modern life.

A snapshot of the 2015 program…San Diego State University (SDSU) will host the first-ever STEM

College Connections Fair. The event will feature a college expo, with representatives from 40 to 50 colleges and universities from across the U.S., to answer questions about their STEM degree programs. Students will also be able to learn more about college life and future STEM careers at several Q&A panel discussions.

Heard of cyanotyping? Do you know anything about it? You will after visiting the High Tech High International (high school level Bright Idea Society winners) booth on EXPO Day. By mixing emulsions from raw chemicals and placing various objects and photos on photosensitive paper, visitors will create their own cyanotype pictures to take home.

How about CSI So Cal? Tour the Escondido Police Department, where the Crime Lab and Traffic Division will showcase how

they gather data and conduct experiments during criminal investigations. Officers and laboratory technicians will explain how scientific principles are used daily to solve crimes and reconstruct traffic collisions.

Looking for a VIP Experience? Take a behind-the-scenes lab tour at Scripps Institution of Oceanography. View the Hydraulics Lab, featuring a wind/wave channel, a wave flow channel, a deep tank and pressure testing. Learn about the Coastal Data Information Program (CDIP), which specializes in wave measurement, swell modeling and forecasting and analyzing coastal environment data.

See the CDIP buoys and learn from the team how they are built and deployed around the world’s oceans.

Embrace your artistic side by viewing the honorees of our inaugural STEM Design contest and participating in a live painting experience inside Petco Park.

Be a part of the “Second Hour of Code” and help the Festival get into the Guinness Book of World Records, by participating in the largest K-12 coding event ever attempted in one place! This event

will be hosted by Microsoft and will take place inside the stadium with a live lesson from our dugout stage! In addition, Microsoft will hold their special experience lounge in the Omni Premier Club inside of PETCO.

Be sure to head over to www.lovestemsd.org to see our full events listing and plan your itinerary for the week. Many of the activities are free and can accommodate school groups, scout troops students and families. EXPO Day, on March 21 at PETCO Park, is FREE and open to the public.

The Festival believes that encouraging young students and families to engage in STEM is a stepping stone to strengthen our communities and foster the next generation of trendsetters for San Diego. Please join us, and embrace the learning and fun, March 14 - 21, 2015.

Sara Pagano is the Managing Director of the San Diego Festival of Science & Engineering

SCIENCEFESTIVAL

Come Ignite Your Love for STEM

By Sara Pagano, Managing Director, SD Festival of Science & Engineering

PRESENTED BY

“Through programs like the San Diego Festival of Science & Engineering we can inspire tomorrow’s leaders to pursue educational opportunities that will further San Diego’s legacy of innovation, grow our economy, and ultimately, create products that change the world.” - Jay Flatley CEO, Illumina


Biocom is the largest regional life science association in the world with more than 650 member companies, most residing right here in San Diego. As a member-driven organization, we work day and night to bring you value – strategically, financially and operationally – through a diverse range of programs and initiatives.

In Biocom’s 20 years of serving the San Diego life sciences community, the Biocom Purchasing Group has been an evolving partner, discovering the science of savings for our members. We are an entity geared toward leveraging our members’ hundreds of millions in collective purchasing power to obtain discounts from vendors in five fundamental categories: data and communications, facilities & operations, HR and finance, lab supplies and travel.

In 2014 alone, we saved our members more than $90 million.One area where Biocom has made a tremendous impact on the

bottom line is our members’ facility and daily operational needs. Our members move, expand, downsize, build out and change their footprints quite frequently here in Southern California. Over the past two decades, Biocom has been an instrumental partner in these efforts.

As we head into Biocom’s 20th year, our strategic goal is to play a stronger role developing our life sciences community. That means building on our members’ current footprints and ensuring pharma and biotech companies see the value of continuing to do business here in San Diego.

This is how our new initiative, Biocom Your Move, was formed.

Your Blueprint for Success We understand the many factors that need to be considered

during a corporate move, expansion or relocation. We have moved twice in the last twelve months, and we strongly believe that the most crucial component to a successful move is finding a comprehensive moving team that offers a wide variety of resources and dedicated service partners who specialize in meeting your needs.

Whether you are planning a move, expansion or facility reconfiguration, Biocom can help you save valuable time and money through our portfolio of vetted suppliers and an expanded network of consultants who specialize in meeting your unique life sciences needs. From decommissioning existing labs, starting up news ones, designing innovative workspaces, sourcing furniture and establishing IT systems and the technologies that will power them, Biocom is a partner you can count on for your next successful move.

Your One-Stop Shop Our endorsed suppliers have gone through rigorous RFPs and

were chosen as best-in-class by an ad hoc committee of key industry Biocom members. Fourteen of these suppliers offer significant discounts to Biocom members, as well as specific terms and conditions and exceptional service commitments to streamline a corporate move.

These suppliers are committed to working with you and your internal task force to devise a moving plan that eliminates stress, minimizes downtime and disruptions and allows for a seamless office transition. They even have experience working with each other since joining our portfolio and have worked out a system to streamline projects and communication.

The Biocom Your Move initiative is an extension of an already solid framework within the Biocom Purchasing Group portfolio of savings. Let us equip you with a great set of tools to provide true value and savings for your company.

As you begin to focus on the best way to transition to your new environment, remember to secure an award-winning corporate relocation team to manage your move. Contact Biocom’s Member Benefits Manager, George Bonaros, at 858.455.0300 x107 to get started on building your team today.

Rick Fultz oversees membership and sponsorship efforts, business development opportunities, and the Biocom Purchasing Group.

PURCHASING GROUP By Rick Fultz,

Managing Director, Biocom Purchasing Group

Biocom Your Move


Your Name: Miranda BivenJob title: Partner

Favorite movie: Charade (with Carey Grant and Audrey Hepburn)Favorite book: Lie Down in Darkness by William Styron, but Sheila, The First Hippo on the Moon by David Walliams is a close second Favorite quote: “Freedom is the freedom to think otherwise” (Rosa Luxemburg)Favorite TV show: MI5 (a British BBC series which is not showing anymore), or for something current, Orphan BlackFavorite restaurant or meal: It’s still almost anything my mother cooks Favorite city: SydneyFavorite actor/actress: Helen MirrenFavorite thing to do on the weekends: Going to the beach with my family – it’s the best way to wear out two small boysWhat CD can we find in your car: The WigglesFavorite hobby: ReadingFavorite website: Sydney Morning Herald (www.smh.com.au) for some news from home Favorite spot in Southern California: My house in Solana Beach when it’s not under constructionFirst job: A waitress - it only lasted 2 hours and I didn’t get paid. Does that count? Favorite part of your job: Meeting and working with interesting and entrepreneurial people If you could have another career, what would it be: A doctor or, in my less practical moments, a staff writer for the The New YorkerWhy did you start working in your industry: Surprisingly, there was not a huge demand for people with a thesis in 1920s Jazz history. I was also interested in the intersection between law and new scientific developments (at the time, it was the early days of embryonic stem cell research, the human genome project and cloning) so representing life sciences companies was a good way to combine those interests.

www.wsgr.com

Name: Jennifer L. BrownJob title: Executive Director, Assurance and Advisory Business Services – Life Sciences

Favorite movie: The Blind Side, Sweet Home AlabamaFavorite TV show: CastleFavorite restaurant or meal: Steak and LobsterFavorite city: San Diego (of course! Since I am a native)Favorite actor/actress: Sandra BullockFavorite thing to do on the weekends: Go to the movies with the family, enjoy all San Diego has to offerWhat CD can we find in your car: Blake Shelton or The Band PerryFavorite hobby: Photography/ScrapbookingFavorite website: Shutterfly (for sharing pictures and managing all my daughter’s Girl Scout Troop activities where I am the Troop Leader – Need any Thin Mints?)Favorite spot in Southern California: Torrey Pines State ParkFirst job: Roundtable Pizza (High School) making pizzas!Favorite part of your job: Helping early stage biotech companies succeed in raising capitalIf you could have another career, what would it be: TeacherWhy did you start working in your industry: Working in public accounting is a good way to learn about different types of business and industries, how successful companies operate and the pitfalls to avoid in creating business policies and practices when starting a business. With this background and experience you can move on in many different directions. I ended up going into industry and then returning to public accounting when I joined EY 20 years ago and made it my career. I enjoy helping my emerging biotech clients strengthen the financial aspects of their businesses to help them succeed in pursuing their research and development goals.

PREMIUM MEMBER SPOTLIGHTS

www.ey.comAbbVieAirgas*Alexandria Real Estate EquitiesAltheaArena PharmaceuticalsBayer HealthcareBiomed Realty TrustBiospaceBP BiofuelsCalifornia Manufacturing Technology

ConsultingCanale CommunicationsCelgeneCity National BankCOI PharmaceuticalsConatus PharmaceuticalsCooley LLPDeloitteDLA PiperEli LillyErnst & YoungFerring Research InstituteFisher ScientificFoley & LardnerGE Healthcare Life SciencesGenoptixHologicJ-LabsJones DayKPBSLatham & WatkinsMallinckrodt PlcMentusMerck Research Laboratories of San DiegoMintz, Levin, Cohn, Ferris, Glovsky and PopeoNuVasiveOffice Depot*PatheonPfizerPraxairPrometheus LaboratoriesPwCThermo Fisher ScientificUnisource SolutionsVWR InternationalWilson Sonsini Goodrich & Rosati

PREMIUM MEMBERS

* New Members from October 2014 to January 2015


Name: Matthew GrantJob title: Associate

Favorite movie: Life is Beautiful (1997)Favorite book: Biographies, generallyFavorite quote: “True happiness is not made in getting something. True happiness is becoming something.” - Marvin J. AshtonFavorite TV show: College footballFavorite restaurant or meal: Steak and potatoesFavorite city: Washington, D.C.Favorite actor/actress: Denzel WashingtonFavorite thing to do on the weekends: Any new adventure with my wife and kidsWhat CD can we find in your car: “Frozen” soundtrack right now (thanks to my daughters)Favorite hobby: SnowmobilingFavorite website: ESPN.comFavorite spot in Southern California: Torrey Pines bluffsFirst job: Janitor at a sheet metal manufacturing plant when I was 14Favorite part of your job: Finding creative solutions to clients’ problemsIf you could have another career, what would it be: High school teacherWhy did you start working in your industry: I like working with a variety of clients, most of whom are successfully developing and/or marketing really fascinating products and services that improve a lot of peoples’ lives

Name: Carolyn Lemm Job title: Director of Business Operations for the Late Phase Strategy, Development, Submission, and Lifecycle Management Group

Favorite movie: Rear WindowFavorite book: Too many – love crime and suspense novelsFavorite quote: “You can’t use up creativity. The more you use, the more you have.” –Maya AngelouFavorite TV show: Modern FamilyFavorite restaurant or meal: Italian, Italian, ItalianFavorite city: Sydney, AustraliaFavorite actor/actress: Harry Connick, Jr. – an amazing actor and musical talentFavorite thing to do on the weekends: Spending time with my children doing just about anythingWhat CD can we find in your car: Dave Matthews Band (Under the Table and Dreaming)Favorite hobby: Cooking and attending live theater, music, or sporting eventsFavorite website: Pinterest Favorite spot in Southern California: My homeFirst job: Dance Instructor for childrenFavorite part of your job: Helping others achieve success and solutionsIf you could have another career, what would it be: A Travel Writer or Arts Critic Why did you start working in your industry: Destiny… My background is Accounting & Finance and I never excelled in science courses, yet I married a scientist and now work in the healthcare industry. I am so thankful to be part of Pfizer working with talented colleagues everyday bringing medicines and therapies to patients. Why did you start working in your industry: Unbelievably large amount of fun.

PREMIUM MEMBER SPOTLIGHTSwww.lw.comwww.pfizer.com

Make Your Mark in BiotechnologY

The Professional Science Master’s in Biotechnology from CSUSM is a degree that leads to jobs with graduates reporting a 97% employment rate at time of graduation. This innovative degree incorporates advanced biotechnology coursework and laboratory training with MBA-level business courses. The part-time evening program accommodates the needs of working professionals. Our graduates are well-prepared for successful careers and advancement in the life science industry.

For more information contact us at www.csusm.edu/el/psmlifelines

Professional Science Master’s

APPLY TODAY!

BOARD OF DIRECTORS

COMMITTEE LEADERSHIP

BOARD OFFICERS AND EXECUTIVE COMMITTEE:CHAIR: Theodore Schroeder*VICE CHAIR: Carin Canale-Theakston, Canale Communications*CHAIR ELECT: Daniel Burgess*VICE PRESIDENT AND GENERAL COUNSEL: Lisa Haile, Ph.D., DLA Piper*VICE PRESIDENT – FINANCE: Daniel Kleeburg, Ernst & Young*VICE PRESIDENT AND SECRETARY: Brent D. Jacobs, Cushman & Wakefield*CHAIR EMERITUS: Magda Marquet, Ph.D., Althea (A member of the Ajinomoto Group)* PRESIDENT & CEO: Joe Panetta, Biocom*Vincent Anido, Ph.D., Aerie PharmaceuticalsSteven Bartz, Ph.D., Merck & CompanyScott Biel, Mintz, Levin, Cohn, Ferris, Glovsky & PopeoMichael Boyd, AbbVieMichael Brown, Stradling Yocca Carlson & RauthTerrance J. BruggemanJohn M. DunnStephen Ferruolo, J.D., Ph.D., USD School of Law*M. Wainwright Fishburn, Jr., Cooley LLP*Don Fitzgerald, GenentechJack FlorioGregory Fond, Sanofi Global R&DGregory Frost, Intrexon Corp.Carol GallagherJeffrey W. Guise, Ph.D., Wilson, Sonsini, Goodrich & RosatiJason Hannon, NuVasiveRichard Heyman, Ph.D.Jim HinrichsElliot Hirshman, Ph.D., San Diego State UniversityMatthew Hudes, Deloitte LLPGuy J. Iannuzzi, MentusGerald Joyce, M.D., Ph.D., Genomics Institute of the Novartis Research FoundationDavid Kabakoff, Ph.D., Sofinnova VenturesSteve Kaldor, Ph.D., QuanticelKatherine Kantardjieff, Ph.D., California State University San MarcosPaul Laikind, Ph.D., ViaCyteJacob Levin, Ph.D., UC IrvineJames Levine, Sapphire Energy*Jack Lief, Arena Pharmaceuticals, Inc.*John Lister, Dexcom

Steven Mento, Ph.D., Conatus Pharmaceuticals, Inc.*William Molloie, PwCTracy Murphy, Biomed Realty TrustPaul Negulescu, Ph.D., Vertex Pharmaceuticals, Inc.*Perry Nisen, M.D., Ph.D., Sanford-Burnham Medical Research InstituteBrian O’CallaghanKenneth Polin, Jones DayTrindl Reeves, Barney & Barney LLC*Gregory Reyes, M.D., Ph.D., CelgeneDan Ryan, Alexandria Real Estate EquitiesCamille Saltman, Malama Composites, Inc.James Schaeffer, Ph.D., Calibr*Christophe Schilling, Ph.D., Genomatica, Inc.*Timothy Scott, Pharmatek*Bhasker Shetty, Ph.D., Pfizer La JollaLarry Stambaugh, Kalos Therapeutics*Mark Stevenson, Thermo Fisher Scientific*Tsuneo Takahashi, NF CorporationScott N. Wolfe, Latham & Watkins

LIFE DIRECTOR:Kennon W. Baldwin, Ferguson Pape Baldwin Architects*David Hale, Hale BioPharma Ventures*Tina Nova, Ph.D., Ilumina

Biocom Board Members-Ex-Officio:Sandra Brown, Ph.D., UCSDMark Cafferty, San Diego Regional Economic Development CorporationConstance Carroll, Ph.D., San Diego Community College DistrictScott Lippman, MD, Moores Cancer Center, UCSDGreg McKee, CONNECTPeter Preuss, The Preuss FoundationJerry Sanders, San Diego Regional Chamber of CommerceDavid Webb, Ph.D., Scripps Research Institute

*Executive Committee Member

Biocom institute Board committee*Steven J. Mento, Ph.D., Conatus Pharmaceuticals, Inc.

capital development committee*Carin Canale-Theakston, Canale Communications

David Kabakoff, Ph.D., Sofinnova Ventures

cro committee

Timothy Scott, Pharmatek

environmental, HealtH and safety committeeCliff HannaDan Shiel, Pfizer La Jolla

facilities committeeAndy Darragh, Ferguson Pape Baldwin Architects

Brent D. Jacobs, Cushman & Wakefield

fda committeeMagda Marquet, Ph.D.,Althea (A member of the Ajinomoto Group)Michele Yelmene, Pharmalink Consulting

intellectual property and patent law committeeDaniel Hart, Knobbe Martens Olson & Bear LLPMichael Mueller, Conatus Pharmaceuticals

international committee

Kenneth Polin, Jones Day

legislative committeeRichard LedfordApril Grant, Sunovion Pharmaceuticals

medical device committeeMike Oliver, Spectra Science

Joleen Schultz, Rady School of Management, UCSD

digital HealtH committee

Kira Jenkins, Biocom

puBlic policy oversigHt committee*Larry Stambaugh, Kalos Therapeutics

Paul Laikind, ViaCyte

purcHasing Board committee*Jack Lief, Arena Pharmaceuticals, Inc.

scHolarsHip committeeBente Hansen, BenteHansen and Associates

veterans committeeJosh Vocovic

*Board Level Committees


BIOTECHNOLOGYAbcore*AbgentAbide TherapeuticsAbwiz BioACADIA PharmaceuticalsActivX BiosciencesAdvanced BioMatrixAdvanced Targeting SystemsAerie PharmaceuticalsAfraxisAgena BioscienceAM ChemicalsAMBRXAmbryx BiotechnologyAmgenAmicrobeAmplyx PharmaceuticalsAnaptysBioAndroScienceAnsun BiopharmaApricus BiosciencesArcturus TherapeuticsArdea BiosciencesArrayomicsAstellas PharmaaTyr PharmaAuspex PharmaceuticalsAvantgenAvelasAvidity NanoMedicinesAviva BiosciencesBachem AmericasBASFBioLegendBiomatricaBiomyxBioNano GenomicsBionomicsBio OptionsBioSpyder TechnologiesBioWaBoehringer-IngelheimCurtana PharmaceuticalsCalciMedicaCannaVest CorporationCARBOGEN AMCISCebix

Cell ApplicationsCelladonCellana Center for Aquaculture TechnologiesChubu Technology Licensing OfficeCibusCidara TherapeuticsCoda TherapeuticsConju-ProbeContract BioticsCrinetics PharmaceuticalsCustopharmCypher GenomicsDart NeuroscienceDefiniensDiomics Corporation*DNAtrixDSM Food SpecialtiesE&B TechnologieseFFECTOR TherapeuticsElcelyx TherapeuticsElectronic BioScienceseMoleculesEpeius BiotechnologiesEquitech BioEton BioscienceFabrusFate TherapeuticsFormexGenelux CorporationGenentechGenlantisGenoa PharmaceuticalsGenomaticaGenovo CorporationGenSignia Life SciencesGigaGen*GlaxoSmithKlineGlobal Medical & Research

TechnologiesGuangdong Consun Pharmaceutical

CompanyGWR InstrumentsHalozyme TherapeuticsHistogenHuman LongevityHuya Bioscience InternationalIDEXX BioResearchIllumina

Imprimis PharmaceuticalsInception SciencesInhibrxInnoPepInnovative Cell TechnologiesInovio PharmaceuticalsIntegrated DNA TechnologiesIntercept PharmaceuticalsInternational Stem CellIntrepid TherapeuticsIntrexon CorporationIntrinsic LifeSciencesInvetechInvivoGenIRBCo.ISIS PharmaceuticalsJ-Oil MillsJSR MicroKalos Therapeutics*Kalyra PharmaceuticalsKoltan PharmaceuticalsKura Oncology*Kyowa Hakko Kirin CaliforniaLa Jolla BiologicsLa Jolla Pharmaceutical CompanyLigand PharmaceuticalsLpathLumena PharmaceuticalsMabVax TherapeuticsMalama CompositesMast TherapeuticsMEI PharmaMeritage PharmaMiltenyi BiotechMirati TherapeuticsMonsantoMultiVirNautilus EnvironmentalNeotheticsNeuroGenetic PharmaceuticalsNF Techno CommerceNitto Denko TechnicalNovartis PharmaceuticalsNovo NordiskNucelisOcera TherapeuticsOhr PharmaceuticalsOptimum TherapeuticsOrexigen Therapeutics

OrPro TherapeuticsOtonomyPacira PharmaceuticalsPanmira PharmaceuticalsPatara Pharma*Pathway GenomicsPersImmune*PfenexPharmAkeaPolaris GroupPolynomaPolyPeptide GroupPredictive BiologyPrimaPharmPrimeGen BiotechPrimordial GeneticsPrognosys BiosciencesProSciQED BioscienceQingdao Ming Yaotang Medical

TechnologyQingdao Newsummit New Drug Public

Service R&D PlatformQuanticel PharmaceuticalsReceptosRegulus TherapeuticsREKA HealthRempex PharmaceuticalsRenova TherapeuticsRibomed BiotechnologiesRidgeline EngineeringRoche Applied ScienceRohto PharmaceuticalRQX PharmaceuticalsRuiYiSapphire EnergySamumedSamsara Sciences*SanofiSciencescapeScripps LaboratoriesSenju USASenomyxSentéSeragon PharmaceuticalsSG BiofuelsSilicon Biosystems*Sirenas Marine DiscoverySolstice Biologics

SomaLogicSophiris BioSorrento TherapeuticsSOVA PharmaceuticalsStemedica Cell TechnologiesSunovion PharmaceuticalsSynteractHCRSynthetic GenomicsTakeda Pharmaceuticals U.S.A.Tanabe Research LaboratoriesTEGA TherapeuticsTenova PharmaceuticalsThesan PharmaceuticalsTocagenTonbo BiosciencesTP TherapeuticsTracon PharmaceuticalsTragara PharmaceuticalsTriphase AcceleratorTrius TherapeuticsUCBUS Specialty LabsVala SciencesVantari GeneticsVaxiion TherapeuticsVerdezyneVertex PharmaceuticalsVet-StemViaCyteVicalViking TherapeuticsVisionary PharmaceuticalsVital TherapiesWellspring BiosciencesWildcat Discovery TechnologiesWorld Fusion US* Xencor*Xycrobe TherapeuticsZogenix

PREMIUMAbbVieAirgas*Alexandria Real Estate EquitiesAltheaArena PharmaceuticalsBayer HealthcareBiomed Realty TrustBiospaceBP Biofuels

California Manufacturing Technology Consulting

Canale CommunicationsCelgeneCity National BankCOI PharmaceuticalsConatus PharmaceuticalsCooley LLPDeloitteDLA Piper

Eli LillyErnst & YoungFerring Research InstituteFisher ScientificFoley & LardnerGE Healthcare Life SciencesGenoptixHologicJ-LabsJones Day

KPBSLatham & WatkinsMallinckrodt PlcMentusMerck Research Laboratories of

San DiegoMintz, Levin, Cohn, Ferris,

Glovsky and PopeoNuVasiveOffice Depot*

PatheonPfizerPraxairPrometheus LaboratoriesPwCThermo Fisher ScientificUnisource SolutionsVWR InternationalWilson Sonsini Goodrich &

Rosati

BIOCOM MEMBERSHIP



NON-PROF I TAmerican Cancer Society, Border

Sierra RegionBattelleCA Institute for Regenerative MedicineCalibrCalifornia Baptist University,

College of EngineeringCalifornia Medical Innovations

InstituteCalifornia State University, San MarcosCity Of MuriettaCONNECTConsulate Of CanadaCSU,CSUPERB ProgramHuman BioMolecular Research

InstituteInstitute of Engineering in Medicine

ISM San DiegoJ. Craig Venter InstituteKaiser PermanenteKOTRA - Los AngelesLa Jolla Bioengineering InstituteLa Jolla Institute for Allergy &

ImmunologyLawrence Family Jewish Community

CenterLos Angeles Biomedical Research

InstituteMedicon Valley AllianceMiraCosta College Biotech ProgramMt. San Jacinto CollegePhRMAPoint Loma Nazarene UniversityQuebec GovernmentRady School Of Management, UCSDSalk Institute For Biological Studies

San Diego Biomedical Research Institute

San Diego Blood BankSan Diego Clinical and Translational

Research Institute, UCSDSan Diego Community College DistrictSan Diego Employers AssociationSan Diego Natural History MuseumSan Diego Regional Chamber of

CommerceSan Diego Regional Economic

Development Corp.San Diego Supercomputer Center

(UCSD)San Diego Workforce PartnershipSanford-Burnham Medical Research

InstituteScottish Development InternationalScripps Health

Scripps Research InstituteSwedish American Chamber Of

Commerce San DiegoThe BioIndustry AssociationThe Lowy Medical Research Institute

(LMRI)Torrey Pines Institute for Molecular

StudiesUC San Diego ExtensionUCI’s Office of ResearchUCSD, Department of BioengineeringUCSD, Health Systems- Center for

Occupational & Environmental Medicine

UCSD, Office of AdvancementUCSD School of MedicineUCSD, Technology Transfer OfficeUK Trade & InvestmentUniversity of San Diego

INDIV IDUALAntoinette AzevedoBernard KingCarol GallagherDonna JansonElliot ParksGary FriedmanJohn DunnJohn KavanaghJulie AmesPeter PreussRichard Ledford

MEDIC AL DEV ICE & D IAGNOST ICAcon LaboratoriesAethlon MedicalAlphatec SpineAltheaDxApplied ProteomicsAstute MedicalAxonics Modulation Technologies*Banyan BiomarkersBeneChillBioceptBioDxBiological DynamicsBiomericabioTheranosticsBreathe TechnologiesBruin BiometricsCell IdxCeloNova BioSciences

CelulaCliniqa CorporationClinMetCompellonCRISI Medical SystemsCritical DiagnosticsCure CareCTK BiotechCVAC SystemsCytori TherapeuticsDermTech InternationalDexComDiagnostic Consulting NetworkDorsa Vi USAEllipse TechnologiesEmerge DiagnosticsEndologixEnigma DiagnosticsEntra Health SystemsEpic SciencesEpitope Diagnostics

Fallbrook EngineeringFemCapFortimedix USAFreedom MeditechGenWay BiotechGlaukos CorporationGlysensHitachi Chemical Research CenterHygeia MedicalIchor Medical SystemsIgnytaImpediMedImThera MedicalInari Medical*Inceptus MedicalINOVA DiagnosticsInterpretaInterventional SpineInVision Biomedical GroupInvivoscribe TechnologiesIonian Technologies

IvantisIvera MedicalKFx MedicalLiferiverMARDX DiagnosticsMedipacs*Micell TechnologiesMillennium HealthNano Imaging ServicesNanomedical DiagnosticsNuFACEOmniomeOncoSec Medical OrganovoParallel 6*Pediatric Bioscience*Prometheus LaboratoriesQualigenQuidelQuinn MedicalReShape Medical

REVA MedicalReVision OpticsRidge DiagnosticsRoka BioscienceSequenomSequent Medical*ShireSienna LabsSirigenSonendoSpectraScienceSuneva MedicalTandem DiabetesTargesonTherOxTristan TechnologiesTrovageneUptake MedicalYulex

BIOCOM MEMBERSHIP

CRO/CMOAbbiotecAbsorption SystemsAccelagenAccugent LaboratoriesAcurianAdvantar LaboratoriesAgility ClinicalAlliance Protein LaboratoriesAmbit BiosciencesAmerican Peptide CompanyAnaBiosAnimantis*Annova ChemARIANNEAthelnBeaufort CRO

Behavioral PharmaBend ResearchBioAgilytix LabsBioAtlaBioserv CorporationBTS ResearchCalChem SynthesisCassiaCato ResearchCharles River LaboratoriesChemDivCombi-BlocksConcortis Biosystems CytelligenDavos ChemicalDD StudioDenovo BiomarkersDrug Delivery Experts

EpistemeStudySiteExon BioSystemsExpertise EngineeringExplora BioLabsGENEWIZGRAM LaboratoriesHamari Chemical San Diego Research

CenterHD Biosciences*Huntingdon Life SciencesIMS Health*Integrium Clinical ResearchInterplex SunbeltinVentive Health ClinicalIriSysJadeBioLCMS Solutions

MediconomicsMicroConstantsMolecular ResponseMPI ResearchMy Chem LLC*NeuroserviceNeuro-SysOOxesis BiotechPacificGMPPharPoint ResearchPharmatek LaboratoriesProfil Institute For Clinical ResearchPSI CROPuracypQuadrants ScientificRetroViroxReveal BiosciencesRho

Robarts Clinical TrialsRoowinSAFC PharmaSherpa Clinical PackagingSpaulding Clinical ResearchStarfish MedicalTherapeutics, Inc.Tioga ResearchToxikonTriligent InternationalUltimate LabsVerum.usVIRAPURWax-It Histology ServicesWuXi AppTecZensun USAZyagen



KEY PROVIDERBarney & BarneyCushman & WakefieldOracle Health SciencesQualcommSan Diego Gas & Electric

PROVIDER2ConnectAccelrysADVIAER TravelAIS Data CentersAlexander’s Mobility ServicesAMN HealthcareAssay DepotAustin CommercialBank of America*Beckloff AssociatesBench InternationalBente Hansen & AssociatesBerkshire Hathaway Home Services Bionest PartnersBioSurplusBiotech PrimerBiotech VendingBioTixBlue Sky BroadcastBootstrap Incubation

Caliber Associates California Commercial SecurityCambridge Research BiochemicalsCanteen Vending ServicesCBREChina Business PartnersChubb Group of Insurance CompaniesClinigen HealthcareControlled Contamination ServicesCorningCovisint CorporationCox BusinessCSCICymerDomain AssociatesEBD GroupElsevierEntereyEquipNetEuretosExp U.S. ServicesFerguson Pape Baldwin ArchitectsFisher & PhillipsForward VenturesFragomen, Del Rey, Bernsen & LoewyFrench BiobeachFrequentzGable PRGamxing*GenslerG/M Business Interiors

Grande ColonialHartl Team- Private Banking &

Investment Group- Merrill LynchHaworthHCP Life Science EstatesH.G. Fenton CompanyHyatt Regency La Jolla at AventineIBM Life SciencesInnovative Lease ServicesJ.T. MacMillan PhotographyJackson & Blanc HVAC ContractorsJones Lang LaSalleKilroy RealtyKnobbe, Martens, Olson & BearLeadership EdgeLegacy Partners CommercialLonza AG*Managed Laboratory Services*Managed SolutionMayer Hoffman McCannMcKenna Long & AldridgeMedidata SolutionsMedline IndustriesMehlman BarnesMercury FundMorgan, Lewis & BockiusMorrison & FoersterOccupational ServicesOrion International Patent OfficeOutlier SolutionsOxford Finance

Pharmalink ConsultingPR NewswirePrevost ConstructionProcopio, Cory, Hargreaves & SavitchProject Management AdvisorsRetirement DNASan Diego World Trade CenterSartoriusSecureDocsScient Federal Credit Union Sharp Business SystemsSheppard Mullin Richter & HamptonShred San DiegoSignature AnalyticsSilicon Valley BankSLM GroupSofinnova VenturesSonceboz Corporation Square 1 BankS Squared Executive SearchStradling Yocca Carlson & RauthSavills StudleySughrue MionSynergy Corporate HousingTata America InternationalTechnical Safety ServicesThe Business Cleaning CompanyThe HealthEd GroupThe Sandler GroupThomas, Mcnerney & PartnersTime Warner Cable

T-Mobile USAUnifirst*United Parcel Service (UPS)VDP DirectVeoliaVirgin AmericaWCCT Global

Achieve professional success through Life Science continuing education programs.Through cutting-edge workshops and events, UC San Diego Extension’s offers cutting-edge workshops and events that enhance skills development in critical Life Sciences occupations. These programs attract both individuals and organizations alike.

Medicinal Chemistry Intensive ProgramApril 20-24, 2015

This accelerated 1-week program focuses on the chemistry of drug molecules and drug action. It covers topics essential for understanding the multidisci-plinary areas of medicinal chemistry as taught by a variety of experienced pharmaceutical and biotechnology professionals. Attendees will leave with an increased understanding of the key concepts in medicinal chemistry as related to drug discovery, a reduced barrier to creative contribution and discussion with biological collaborators, and an increased awareness of the meaning and relevance of biological data and the limitations of its interpretation

In Vitro Diagnostics Product DevelopmentMay 1 & 2, 2015

Explore the issues in moving an IVD product from concept to regulatory approval and market launch. Although the focus is on IVD product development much of the material is applicable to product development in other areas of biotechnology and pharmaceuticals.

• Understand the IVD product development process - beginning to end• Learn the “language” of IVD• Think like an IVD product developer

Mammalian Cell Culture TechnologyJune 3-5, 2015

This 3-day workshop is designed to provide a deep understanding of the perfor-mance of mammalian cell culture operations throughout the product and process life cycle from process development to full scale manufacturing under current Good Manufacturing Practices. In addition to cell line and process development, this workshop will explore insights into technology transfer, scale–up, and operational aspects. State of the art regulatory and quality practices will play a central role.

Microbial Fermentation WorkshopAugust 12-14, 2015

Taught by faculty and practitioners, this 3-day workshop is designed to provide a deep dive into bioreactor operations for microbial fermentations and equip you with the knowledge and practical skills needed to optimize your processes. You will also explore bioprocess simulation, economics and modern techniques used in applying process analytical technology in manufacturing.

Also included... Fermentor Demonstrations by representatives from DCI Biolafitte!

(858) 534-9353 | [email protected] | extension.ucsd.edu/lifesciences

























10996 Torreyana Rd, Suite 200San Diego, CA 92121-3021

www.Biocom.org

Please send a change of address or subscription request to Sonali Vittachi at [email protected].

g r a e b e l c€¦ · verenium / basf 60,000 sf tenant representation genzyme / sanofi 64,000 sf...

Documents